Cognition Therapeutics, Inc. provided an update on a biomarker analysis from its Phase 2 SHINE study in mild-to-moderate Alzheimer’s disease, focusing on participants with lower levels of plasma p-tau217. This analysis identified several blood-based measures of Alzheimer’s disease biology that were normalized in CT1812-treated participants compared to placebo.
These biomarker changes occurred in conjunction with a 95% slowing of cognitive decline, as measured by ADAS-Cog11, in the same patient group. The robust clinical benefit represented a 2.7-point improvement on ADAS-Cog11 versus placebo over the six-month study duration.
The results demonstrated normalization of key indicators of Alzheimer’s disease progression, including glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta (Aβ). These findings provide further evidence that CT1812 may be preserving cognitive function and slowing disease progression by protecting key neurological systems, supporting its disease-modifying potential.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.